# Apatinib Combined With Capecitabine Second-line Treatment of Advanced Gastric Cancer: a Single-arm Exploratory Clinical Pilot Trial

> **NCT03531931** · — · UNKNOWN · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 20 (estimated)

## Conditions studied

- Progression-free Survival;Progression-free Survival;Disease Control Rate; Safety

## Interventions

- **DRUG:** Apatinib/Capecitatine

## Key facts

- **NCT ID:** NCT03531931
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05
- **Primary completion:** 2023-05
- **Final completion:** 2023-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2018-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03531931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03531931, "Apatinib Combined With Capecitabine Second-line Treatment of Advanced Gastric Cancer: a Single-arm Exploratory Clinical Pilot Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03531931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*